

REMARKS

AMENDMENTS TO THE SPECIFICATION:

Paragraph numbers 0185, 0189, 0193, 0196, and 0201 were amended to append the SEQ ID NO identifier (e.g., SEQ ID NO:82, 83, 84, 85, and 86, respectively) to each consensus sequence disclosed therein in order to conform to 37 C.F.R. 1.821-1.825, and to address the Examiner's objection to Applicants failure to include the same. No new matter has been added.

AMENDMENTS TO THE SEQUENCE LISTING:

Support for the amendments to the Sequence Listing may be found by reference to the Specification, as originally filed, and in the Sequence Listing, as originally submitted.

Specifically, the amendment to line <140> of the Sequence Listing was made to make the Sequence Listing consonant with the assigned U.S. non-provisional serial number for the present application.

Support for amending the artificial sequence definition of SEQ ID NO: 67 as well as the definition for the “n” and “k” nucleotides, may be found in the specification as originally filed, in paragraph number 0290, and on line <223> of SEQ ID NO:67 of the Sequence Listing as originally submitted.

Support for amending the artificial sequence definition of SEQ ID NO: 68 as well as the definition for the “n” and “v” nucleotides, may be found in the specification as originally filed, in paragraph number 0290, and on line <223> of SEQ ID NO:68 of the Sequence Listing as originally submitted.

Support for the newly added sequences SEQ ID NO:82 to SEQ ID NO:86, may be found in the specification as originally filed, and specifically, in paragraph numbers 0185, 0189, 0193, 0196, and 0201. These sequences were added to the Sequence Listing, along with the appropriate lines <221> thru <223>, to conform to 37 C.F.R. 1.821-1.825, and to address the Examiner’s objection to Applicants failure to include the same.

All of Applicant’s amendments to the Sequence Listing were made to conform to 37 C.F.R. 1.821-1.825. No new matter has been added.

Applicants request the originally submitted paper copy and Computer Readable Form of the Sequence Listing be replaced with the paper copy and Computer Readable Form of the Substitute Sequence Listing submitted herewith. Applicants believe the Substitute Sequence Listing is in compliance with C.F.R. 1.821 thru 1.825.

Applicants hereby provide a Computer Readable Form of the Substitute Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Substitute Paper Copy and the Substitute Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same as required by 37 CFR §1.821(f), and 1.825(b). The undersigned also states that the Substitute Paper Copy and the Substitute Computer Readable Form do not contain any new matter as required by 37 CFR §1.821(g).

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: May 29, 2003